Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients

Microarray technology was used to profile miRNA expression in primary tumor and stromal tissue from paraffin embedded material of 51 patients with colorectal cancer. 26 miRNAs resulted differentially expressed with at least 2-fold change in tumor tissue with respect to stroma (16 more expressed in the tumor and 10 more expressed in the stroma). 10/26 were confirmed as differentially expressed at qRTPCR: miR-200c-3p, miR-141-3p, miR-200b-3p, miR-200a-3p, miR-1246, miR-92a-3p, miR-194-5p, miR-192-5p, miR-3651-5p, and miR-574-3p. No significant association was found between miRNA expressions and stage at diagnosis, site of primary tumor, first site of metastasis, progression-free, or overall survival.

[1]  Frank J. Sørensen,et al.  Diagnostic and prognostic microRNAs in stage II colon cancer. , 2008, Cancer research.

[2]  Y. Asmann,et al.  miRNA Expression in Colon Polyps Provides Evidence for a Multihit Model of Colon Cancer , 2011, PloS one.

[3]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[4]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[5]  D. Katsaros,et al.  Title: Mirna Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities Statement of Translational Relevance , 2022 .

[6]  P. López-Romero.  Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library , 2011, BMC Genomics.

[7]  Metin N. Gurcan,et al.  Pten in Stromal Fibroblasts Suppresses Mammary Epithelial Tumors , 2009, Nature.

[8]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[9]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[10]  Marek Svoboda,et al.  MicroRNAs in colorectal cancer: translation of molecular biology into clinical application , 2009, Molecular Cancer.

[11]  DYRK1A kinase inhibitors with emphasis on cancer. , 2012 .

[12]  Xiaonan Fu,et al.  Prognostic role of microRNA‐21 in various carcinomas: a systematic review and meta‐analysis , 2011, European journal of clinical investigation.

[13]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[14]  Paolo G. V. Martini,et al.  Graphite Web: web tool for gene set analysis exploiting pathway topology , 2013, Nucleic Acids Res..

[15]  Y. Cheng,et al.  The prognostic significance of APC gene mutation and miR‐21 expression in advanced‐stage colorectal cancer , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[16]  Tommaso Mazza,et al.  Mirna Expression Profiles Identify Drivers in Colorectal and Pancreatic Cancers , 2012, PloS one.

[17]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[18]  N. Seki,et al.  Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines , 2011, International journal of oncology.

[19]  Hua Lu,et al.  p53 downregulates Down syndrome‐associated DYRK1A through miR‐1246 , 2011, EMBO reports.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  Hsien-Da Huang,et al.  miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions , 2013, Nucleic Acids Res..

[22]  Kenichi Sugihara,et al.  Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters , 2012, Clinical Cancer Research.

[23]  T. Dalmay,et al.  MicroRNAs and the hallmarks of cancer , 2006, Oncogene.

[24]  P. Watson,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[25]  Shinobu Ueda,et al.  miR‐92 is a key oncogenic component of the miR‐17–92 cluster in colon cancer , 2011, Cancer science.

[26]  R. Jove,et al.  miR‐194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice , 2010, Hepatology.

[27]  J. Koenderink.  Q… , 2014, Les noms officiels des communes de Wallonie, de Bruxelles-Capitale et de la communaute germanophone.

[28]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[29]  Jian Lu,et al.  Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.

[30]  R. Kalluri,et al.  Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.

[31]  M. Agostini,et al.  miRNAs in colon and rectal cancer: A consensus for their true clinical value. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[32]  C. Eng,et al.  Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. , 2007, JAMA.

[33]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[34]  R. Kiss,et al.  DYRK1A kinase inhibitors with emphasis on cancer. , 2012, Mini reviews in medicinal chemistry.

[35]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[36]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[37]  A. Rustgi,et al.  The role of the miR-200 family in epithelial-mesenchymal transition , 2010, Cancer biology & therapy.

[38]  Hidetoshi Shimodaira.  An approximately unbiased test of phylogenetic tree selection. , 2002, Systematic biology.

[39]  Xin Zhang,et al.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. , 2008, Cancer research.

[40]  Wei Zhang,et al.  Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis , 2013, Disease markers.

[41]  Christophe Lemetre,et al.  MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease , 2011, International Journal of Colorectal Disease.

[42]  K. Mimori,et al.  Over- and under-expressed microRNAs in human colorectal cancer. , 2009, International journal of oncology.

[43]  L. Hong,et al.  High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. , 2012, Gene.

[44]  David Bryant,et al.  DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists , 2007, Nucleic Acids Res..